Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co (HKSE:02566) Total Current Assets Explanation
In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co's Liquidation Value for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Total Current Assets Related Terms
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Total Current Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Total Current Assets Chart
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Annual Data
Trend
Dec21
Dec22
Dec23
Dec24
Dec25
Total Current Assets
915.79
847.31
918.49
1,505.39
1,638.49
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Semi-Annual Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.
What does a Total Current Assets of HK$1,638 Mil mean?
Hangzhou Jiuyuan Genetic Biopharmaceutical Co (HKSE:02566) has a Total Current Assets of HK$1,638 Mil as of Dec. 2025. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Hangzhou Jiuyuan Genetic Biopharmaceutical Co and its competitors.
Is Hangzhou Jiuyuan Genetic Biopharmaceutical Co's Total Current Assets too high?
Hangzhou Jiuyuan Genetic Biopharmaceutical Co's current Total Current Assets is HK$1,638 Mil. Overall, Hangzhou Jiuyuan Genetic Biopharmaceutical Co has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Jiuyuan Genetic Biopharmaceutical Co's Total Current Assets compare to VRTX and REGN?
Hangzhou Jiuyuan Genetic Biopharmaceutical Co's Total Current Assets of HK$1,638 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Biotechnology company?
A good Total Current Assets depends on the Biotechnology industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Hangzhou Jiuyuan Genetic Biopharmaceutical Co and its competitors. Hangzhou Jiuyuan Genetic Biopharmaceutical Co's current Total Current Assets is HK$1,638 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Jiuyuan Genetic Biopharmaceutical Co stock overvalued right now?
Hangzhou Jiuyuan Genetic Biopharmaceutical Co (HKSE:02566) has a current Total Current Assets of HK$1,638 Mil. The current Total Current Assets is HK$1,638 Mil. Hangzhou Jiuyuan Genetic Biopharmaceutical Co's overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Hangzhou Jiuyuan Genetic Biopharmaceutical Co (HKSE:02566), the current Total Current Assets is HK$1,638 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Ltd is a biopharmaceutical company in China. It is engaged in the research & development, manufacturing, and commercialization of biopharmaceutical products and medical devices. The company focuses on four large and fast-growing therapeutic areas: orthopedics, metabolic diseases, oncology, and hematology. Centered around these therapeutic areas, it has built a diversified product portfolio comprising several marketed products, such as Jilifen, Jijufen, Jiouting, Yinuojia, Guyoudao, etc., and has several product candidates under development, such as JY54, JY23, JY47, JY56, JY29-2, etc., targeting various indications. Geographically, the company generates maximum revenue from the Chinese Mainland, and the rest from other countries.
20GF Score
Get the complete analysis for HKSE:02566
Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02566 has been successfully added to your 
